Shanghai Shyndec Pharmaceutical Co., Ltd. (600420) Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Shanghai Shyndec Pharmaceutical Co., Ltd.

Why is Shanghai Shyndec Pharmaceutical Co., Ltd. ?

Poor long term growth as Net Sales has grown by an annual rate of -4.13% and Operating profit at 7.25% over the last 5 years

Negative results in Jun 25

OPERATING CASH FLOW(Y) Lowest at CNY 770.77 MM
RAW MATERIAL COST(Y) Grown by 102.84% (YoY)
CASH AND EQV(HY) Lowest at CNY 5,109.09 MM

With ROE of 8.91%, it has a very attractive valuation with a 1.06 Price to Book Value

Over the past year, while the stock has generated a return of -8.96%, its profits have fallen by -8.9%
At the current price, the company has a high dividend yield of 2.8

Below par performance in long term as well as near term

Along with generating -8.96% returns in the last 1 year, the stock has also underperformed China Shanghai Composite in the last 3 years, 1 year and 3 months

Real-Time Research Report

Verdict Report

How much should you hold?

Overall Portfolio exposure to Shanghai Shyndec Pharmaceutical Co., Ltd. should be less than 10%
Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock

Is Shanghai Shyndec Pharmaceutical Co., Ltd. for you?

Low Risk, Low Return

Absolute

Risk Adjusted

Volatility

Shanghai Shyndec Pharmaceutical Co., Ltd.

-8.3%

-0.33

18.10%

China Shanghai Composite

26.21%

1.87

14.02%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

-4.13%

EBIT Growth (5y)

7.25%

EBIT to Interest (avg)

20.12

Debt to EBITDA (avg)

0.27

Net Debt to Equity (avg)

-0.32

Sales to Capital Employed (avg)

0.78

Tax Ratio

20.96%

Dividend Payout Ratio

37.13%

Pledged Shares

Institutional Holding

ROCE (avg)

12.64%

ROE (avg)

10.07%

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

1.06

EV to EBIT

6.53

EV to EBITDA

4.20

EV to Capital Employed

1.10

EV to Sales

0.90

PEG Ratio

Dividend Yield

2.79%

ROCE (Latest)

16.82%

ROE (Latest)

8.91%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Mildly Bullish

Bearish

RSI

No Signal

Bollinger Bands

Sideways

Mildly Bearish

Moving Averages

Mildly Bearish (Daily)

KST

Mildly Bullish

Bearish

Dow Theory

No Trend

Mildly Bullish

OBV

Bullish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

0What is working for the Company

NO KEY POSITIVE TRIGGERS

-19What is not working for the Company

OPERATING CASH FLOW(Y)

Lowest at CNY 770.77 MM

RAW MATERIAL COST(Y)

Grown by 102.84% (YoY

CASH AND EQV(HY)

Lowest at CNY 5,109.09 MM

DEBT-EQUITY RATIO (HY)

Highest at 0 %

INVENTORY TURNOVER RATIO(HY)

Lowest at 0%

DEBTORS TURNOVER RATIO(HY)

Lowest at 0%

NET SALES(Q)

Lowest at CNY 2,270.9 MM

OPERATING PROFIT(Q)

Lowest at CNY -1,667.4 MM

OPERATING PROFIT MARGIN(Q)

Lowest at -73.42 %

EPS(Q)

Lowest at CNY 0

Here's what is not working for Shanghai Shyndec Pharmaceutical Co., Ltd.

Operating Cash Flow

Lowest at CNY 770.77 MM

in the last three years

MOJO Watch

The company's cash revenues from business operations are falling

Operating Cash Flows (CNY MM)

Net Sales

Lowest at CNY 2,270.9 MM

in the last five periods

MOJO Watch

Near term sales trend is negative

Net Sales (CNY MM)

Net Sales

At CNY 2,270.9 MM has Fallen at -11.83%

over average net sales of the previous four periods of CNY 2,575.58 MM

MOJO Watch

Near term sales trend is negative

Net Sales (CNY MM)

Operating Profit

Lowest at CNY -1,667.4 MM

in the last five periods

MOJO Watch

Near term Operating Profit trend is negative

Operating Profit (CNY MM)

Operating Profit Margin

Lowest at -73.42 %

in the last five periods

MOJO Watch

Company's profit margin has deteriorated

Operating Profit to Sales

EPS

Lowest at CNY 0

in the last five periods

MOJO Watch

Declining profitability; company has created lower earnings for shareholders

EPS (CNY)

Cash and Eqv

Lowest at CNY 5,109.09 MM

in the last six Semi-Annual periods

MOJO Watch

Short Term liquidity is deteriorating

Cash and Cash Equivalents

Debt-Equity Ratio

Highest at 0 %

in the last five Semi-Annual periods

MOJO Watch

The company is borrowing more to fund its operations; it's liquidity situation may be stressed

Debt-Equity Ratio

Inventory Turnover Ratio

Lowest at 0%

in the last five Semi-Annual periods

MOJO Watch

Company's pace of selling inventory has slowed

Inventory Turnover Ratio

Debtors Turnover Ratio

Lowest at 0%

in the last five Semi-Annual periods

MOJO Watch

Company's pace of selling Debtors has slowed

Debtors Turnover Ratio

Raw Material Cost

Grown by 102.84% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has deteriorated; this may lead to a fall in profit margin

Raw Material Cost as a percentage of Sales